All-trans retinoic acid enhances temozolomide-induced autophagy in human glioma cells U251 via targeting Keap1/Nrf2/ARE signaling pathway

LIN SHI1*, HONGYUAN LI1* and YANG ZHAN2

Departments of 1Neurosurgery and 2Pathology, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China

Received January 18, 2017; Accepted May 17, 2017

DOI: 10.3892/ol.2017.6482

Abstract. The present study evaluated the retinoid acid (RA) enhancement of temozolomide (TMZ) effects on the human glioma cells U251 and explored its underlying molecular mechanism. The cell growth was detected using the MTT assay and the cell cycle was assessed by flow cytometry. Cell apoptosis was analyzed by Annexin V/propidium iodide staining, and the cell morphology was evaluated using transmission electron microscopy (TEM). Additionally, reverse transcription-PCR and western blot analysis were applied to detect the mRNA and protein levels. The RA treatment in combination with TMZ in the human U251 cells further inhibited cells growth, arresting cell cycle progression at the G0/G1 phase, and significantly induced apoptosis of U251 cells. After the RA+TMZ treatment of U251 cells, autophagy associated proteins Beclin 1 and LC3B were significantly increased, and the TEM analysis were consistent with autophagy protein levels. Moreover, Keap1/Nrf2/ARE expression was downregulated significantly, indicating the involvement in the mechanisms that RA treatment could enhance the TMZ effects on U251 cells. RA treatment in combination with TMZ may provide some experimental evidence for the possible effect of RA+TMZ against the growth and proliferation of glioma cells. Therefore, the RA+TMZ administration may have potential utility for glioblastoma treatment.

Introduction

Glioblastoma (GBM) is an aggressive astrocytic neoplasm and one of the main contributors to cancer-associated deaths in adult and pediatric populations (1). Median survival time of GBM patients is approximately 12-15 months after the first diagnosis (2). Conventional treatments for GBM patients are mostly surgical tumor excision followed by chemotherapy or radiation therapy (3). Although the therapies have increased the survival time to approximately 14.6 months, the advantages are unconspicuous (4). Temozolomide (TMZ) was approved for use in radiotherapy for treatment of newly diagnosed GBM in adults and as a maintenance therapy in 2005 (5). TMZ is the most commonly used and first line chemotherapeutic agent for GBM patients, though some other chemotherapeutic drugs could be found as pharmaceutical options (6,7).

Retinoic acid (RA) is a chemotherapeutic and chemopreventive agent (8). It can inhibit tumorigenesis via suppressing the cell growth and stimulating cell differentiation (9). Besides, RA also promotes cellular apoptosis which may be a reason of its antitumor characteristics (10). RA mediated signaling influences the development of the central nervous system through regulating neuronal differentiation process (11), and at early stages adjusting the neurogenesis of adults (12). Autophagy is usually activated in tumors by radiation or chemotherapy (13,14), and this process acts as a potential protector for cancer treatment. Autophagy has been thought as a pro-death or pro-survival response to several external stresses, such as the radiotherapy and chemotherapy at both organic and cellular levels (15). The underlying mechanisms that autophagy has such as seemingly opposite functions remained elusive. A study reported that autophagy relative pathways operate to supply cells with metabolic substrates, leading to cell maintenance in many moderate stimulus conditions (16). However, various studies reported that autophagy, if uncontrolled, also became a contributor to cell death that could occur in the absence of detectable apoptosis signs (17). In addition, one important autophagy hallmark is the conversion of light chain 3A to its lapidated form LC3B (18). Besides, LC3B is the first identified mammalian protein that related to autophagy (19). Beclin 1 is another important autophagy-associated protein, which has been reported to play a central role in neurodegeneration prevention (20).

In the present study, we investigated the the RA potential therapeutic function to enhance the TMZ effects on the U251 cells, and explored the growth, proliferation, and apoptosis of the U251 cells after the RA+TMZ treatment. Moreover, the role of the RA+TMZ was also elucidated on the regulation
of autophagy associated proteins Beclin 1 and LC3B. Most importantly, the underlying mechanisms of RA enhancement to TMZ effects on U251 cells were investigated.

Materials and methods

Cell culture. The human U251 glioma cells line was purchased from the American Type Culture Collection (Rockville, MD, USA). The cancer cell line was cultured in RPMI-1640 containing 10% fetal bovine serum (FBS), 50 µg/ml amphotericin B and 100U/ml penicillin, and maintained at 37°C in 5% CO2 incubator. The control cells were untreated in medium containing vehicle dimethyl sulfoxide (DMSO).

MTT assay. Cells were plated in 24-well plates (5x10^3 cells per well). TMZ and RA at various concentrations were added after cells attachment to the plates. Then after overnight culture, baseline values were obtained by an MTT assay (Life Technologies, Grand Island, NY, USA). It is a colorimetric assay to test viable cells by measuring formazan reduced from MTT. After 20 min of incubation with MTT, we extracted formazan by DMSO and tested the optical density at 540 nm. MTT assay was performed at 48 h. Experiments were performed in triplicate.

Cell cycle analysis by flow cytometry. U251 cells were collected following the TMZ (400 µM) and RA (10 µM) and incubated 48 h. Then the cells were fixed in the ice-cold ethanol (70%) at -20°C overnight. The next morning, the cells were first incubated in the 10 µM RNAse at 37°C for 30 min, then stained with propidium iodide at 4°C for 1 h. Cell cycle analysis was carried out on a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, USA) and the obtained data were analyzed using CellQuest™ software (BD Biosciences).

Cell apoptosis by Annexin V/propidium iodide (PI) double staining. Following treatment with TMZ (400 µM) and RA (10 µM) and incubation for 48 h, the cells for apoptosis analysis were first resuspended in Annexin V binding buffer, and then stained with the FITC-conjugated Annexin V and PI simultaneously at 37°C for 15 min in the dark before adding the binding buffer. Then the apoptotic cells were identified using the flow cytometry analysis on a FACSCalibur system (FacsScan; BD Biosciences).

Transmission electron microscopy (TEM). For the TEM analysis of cell morphological features, cells were first fixed in 3% glutaraldehyde followed by 1% osmium tetroxide, then dehydrated in the graded alcohols and embedded in Epon (Agar Scientific, Stansted, UK). The sections were stained in lead citrate and uranyl acetate and were finally observed with the Morgagni 268d transmission electron microscope (FEI, Hillsboro, OR, USA).

Drug treatment. DMSO, potassium phosphates, Propidium iodide, Tris-HCl, ribonuclease-A, Triton X-100 and Trypan blue were obtained from Sigma Chemical Co. (St. Louis, MO, USA). L-glutamine, DMEM, FBS and penicillin-streptomycin were purchased from Gibco Invitrogen Corp. (Grand Island, NY, USA). TMZ and RA were obtained from Sigma Chemical Co. and dissolved in DMSO to the optimal working concentration.

Western blot analysis. After treatment, the cells were collected and the protein extracted with RIPA lysis buffer. The protein concentrations were quantified by the BCA method. Protein samples (30 µg) were run on 10% gels, and then transferred to the PVDF membrane. After 1 h of blocking with the 5% non-fat milk, the membranes were incubated with the primary rabbit anti-LC3B, the rabbit anti-Beclin 1 antibody, the rabbit anti-Kasp1 antibody, the rabbit anti-Nrf2 antibody, the rabbit anti-ARE antibody (1:1,000; Abcam, Cambridge, MA, USA) at 4°C overnight. Washing in TBST three times, the membranes were then incubated with a peroxidase labeled secondary antibody (1:5,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 2 h. The bands were washed again, enhanced with chemiluminescence reagents and visualized with the ChemiDoc™ MP Imaging System (Bio-Rad, Berkeley, CA, USA).

Reverse-transcription PCR. After treatment, the cortex was collected to determine the expression of Keap1/Nrf2/ARE mRNA by RT-PCR. Total RNA was extracted by the TRIzol RNA extraction reagent (Invitrogen, Carlsbad, CA, USA) following the protocols and quantified by spectrophotometer method. Purified RNA with equal volume was reverse transcribed (RevertAid Fist Strand cDNA Synthesis kit, K1622; Thermo Fisher Scientific, Waltham, MA, USA). RT-PCR analysis was performed using a PCR Thermal Cycler Dice instrument (Takara Bio, Inc., Otsu, Japan).

Statistical analysis. All data were expressed as the mean ± standard error of the mean (SEM), and were analyzed using a one-way analysis of variance followed by Bonferroni-Dunn correction. Statistical analysis was performed using SPSS software, version 20.0 (SPSS, Inc., Chicago, IL, USA).

Results

RA enhances the TMZ effects on inhibition of the U251 cell proliferation. To verify if RA has additive, synergistic or antagonistic effects after administration with TMZ, U251 cells were treated with RA and TMZ at various concentrations and incubated for 48 h. As shown in Fig. 1A, the TMZ IC50 was 691.6 µM while the TMZ+RA IC50 was TMZ 368.7 µM and RA 9.6 µM after incubation for 48 h. As Fig. 2B shown, the MTT assay further confirmed that RA enhanced the TMZ effects on inhibition of the U251 cells proliferation.

RA enhances the TMZ effects on modulation of the U251 cell cycle. The U251 cells were treated with RA and TMZ at an appropriate ratio according to their IC50, respectively, and incubated for 48 h. Then the flow cytometry analysis was performed to investigate the U251 cell cycle according to the cell cycle stage distribution (G0, G1, S, G2 and M). We found a slight G0/G1 phase arrest in the TMZ group and a marked arrest in the RA+TMZ group, elucidating that RA could enhance the TMZ effects on modulation of the U251 cell cycle (Fig. 2).

RA enhances the TMZ effects on induction of U251 cell apoptosis. With the Annexin V/FITC and PI method, the RA ability to enhance the TMZ effects on inducing U251 cell apoptosis
was explored. U251 cell apoptosis was slightly induced in the TMZ group while significantly induced by the RA+TMZ treatment (Fig. 3A). As shown in Fig. 3B, the number of apoptotic cells was markedly increased after treatment with 10 µM RA + 400 µM TMZ compared with the TMZ group (21.6±1.5% vs. 12.4±1.1%).

**RA enhances the TMZ effects on induction of U251 cell autophagy.** In order to assess the presumed autophagy mechanism in U251 cells, we detected the protein levels of autophagy associated proteins Beclin 1 and LC3B with western blot analysis. The LC3B and Beclin 1 levels were slightly upregulated in the TMZ group while significantly increased by the RA+TMZ treatment (Fig. 4A). Furthermore, the results of ultrastructural TEM analysis were consistent with autophagy induction, showing an extensive cytoplasm vacuolization and many single-membrane autophagolysosomes containing cellular debris (Fig. 4B).

**RA enhances the effects of TMZ reducing the Keap1/Nrf2/ARE signaling.** Western blot analysis and RT-PCR were applied to assess the mRNA and protein levels of Keap1/Nrf2/ARE to
explore the underlying mechanisms of RA in combination with TMZ. As shown in Fig. 5, the Keap1/Nrf2/ARE expression was slightly downregulated in the TMZ group while markedly reduced by the RA+TMZ treatment.

**Discussion**

In the present study, the RA potential therapeutic function to enhance the TMZ effects on the U251 cells were evaluated.
Our results suggested that the RA treatment enhanced the TMZ effects on inhibition of the U251 cell growth and arresting cell cycle progression at the G0/G1 phase. Besides, RA+TMZ treatment was able to significantly induce U251 cell apoptosis. Most importantly, the results of ultrastructural TEM analysis were consistent with autophagy protein levels, showing an extensive cytoplasm vacuolization and many single-membrane autophagolysosomes containing cellular debris. Western blot analysis and RT-PCR confirmed the downregualtion of Keap1/Nrf2/ARE signaling pathway involved in the mechanisms that the RA treatment could enhance the TMZ effects on U251 cells.

In spite of the advances in GBM therapies, the overall 5 year survival rate is still less than 5% (21). The efficacy of TMZ is often limited due to the resistance development (22). Studies have found that autophagy played a central role in the drug treatment of GBM. TMZ induces autophagy of glioma cells to produce anticancer effect (23,24). It has been reported that autophagy has close connection with the chemoresistance in glioma cells (25-27). Even though autophagy had a suppressive effect on tumor in normal cells, the autophagy induction may facilitate tumor cells survival, resulting in the resistance to cellular death. However, autophagy could also be involved in the death mechanism that inhibited tumor progression based
on the degree of cellular context and the DNA damage (22). Currently there is no consistent opinion on whether the autophagic death could be considered as a form of the programmed cellular death, or whether it could simply represent dying cells with the autophagic feature (28). In addition, the neurons and brain tissues were the major targets for illuminating how RA deficiency could influence the plasticity, differentiation, and neuronal neurogenesis (29-31), which may explained the reason for the altered behavior induced by the RA deficiency. However, the effects of RA deficiency on the glial cells remain elusive.

The new results in our present study were that the RA treatment in combination with TMZ in the human U251 cells could further inhibit the cells growth, arresting cell cycle progression at the G0/G1 phase, and significantly induced apoptosis of U251 cells. Moreover, after the RA+TMZ treatment of U251 cells, autophagy-associated proteins Beclin 1 and LC3B were significantly increased, and the ultrastructural TEM analysis were consistent with autophagy protein levels. Kep1/Nfr2/ARE expression was significantly downregulated, indicating the involvement in the mechanisms that RA treatment could enhance the TMZ effects on U251 cells. The close correlation between the U251 cells and the RA treatment in combination with TMZ administration may provide some experimental evidence for the possible effect of the RA+TMZ against the growth and proliferation of the U251 cells. The clear mechanisms underlying the RA+TMZ action and its utility for the treatment of GBM cancer in humans still need to be investigated further.

References

1. Hathout L, Ellingson BM, Cloughesy T and Pope WB: A novel bicompartamental mathematical model of glioblastoma multiforme. Int J Oncol 46: 825-832, 2015.
2. Huse JT and Holland EC: Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331, 2010.
3. Bryukhovetskiy JS, Dyuizen IV, Shevchenko VE, Bryukhovetskiy AS, Mischenko PV, Milkina EV and Khotimchenko YS: Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme. Mol Med Rep 14: 4511-4520, 2016.
4. Knisely JP and Baehring JM: A silver lining on the horizon for glioblastoma. Lancet Oncol 10: 434-435, 2009.
5. Nanev M, Gleave MG, Sharif R and Shaikh SM: Autophagic death could be considered as a form of the programmed cellular death, or whether it could simply represent dying cells with the autophagic feature. Autophagy 3: 635-637, 2007.
6. Shinojima N, Yokoyama T, Kondo Y and Kondo S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in malignant glioma cells. Cell Death Differ 11: 448-457, 2004.
7. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in the treatment of glioblastoma. Neuro Oncol 17: 635-637, 2015.
8. Natsumeda M, Maitani K, Liu Y, Miyahara H, Kaur H, Chu Q, Zhang H, Kahlert UD and Eberhart CG: Targeting notch signaling and autophagy increases cytotoxicity in glioblastoma cells. BMC Cancer 15: 990, 2015.
9. Zhang C, Cai Z, Liang Q, Wang Q, Lu Y, Hu L and Lu H: GRP78 depletion enhances autophagic flux in U251 cells. Cell Mol Neurobiol 37: 555-562, 2016.
10. Shinojima N, Yokoyama T, Kondo Y and Kondo S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 3: 635-637, 2007.
11. Mei Z and He C: Polyphyllin VII induces an autophagic cell death involving the JNK pathway and inhibition of PI3K/Akt/mTOR pathway in HepG2 cells. PLoS One 11: e0147405, 2016.
12. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
13. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
14. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
15. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
16. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
17. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
18. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
19. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
20. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
21. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
22. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
23. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
24. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
25. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
26. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
27. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
28. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
29. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.
30. Koya T, Guo FC, Shiozawa S, Komatsu M, Hori M, Kondo Y, Ito H, Kondo S and Ueno T: Autophagy in the molecular pathology of malignant glioma and medulloblastoma. Nat Genet 31: 84-88, 2002.